InFocus BACK TO HOME     Patient Engagement in the Era of CAR-T   BACK TO HOME Patient Engagement Roundtable: A Varied Global Picture As complex cutting-edge therapies come online, industry sponsors are increasingly looking to engage with patients, caregivers, and advocacy groups earlier and more broadly in the drug development…

InFocus BACK TO HOME     Patient Engagement in the Era of CAR-T   BACK TO HOME CGT, Real World Evidence & The Patient Experience One of the enduring conundrums around ground-breaking and potentially paradigm-shifting treatments such as CAR-T is the ever-thorny question of how fast to move them to market…

InFocus BACK TO HOME     Patient Engagement in the Era of CAR-T   BACK TO HOME CAR-T and the Art of Managing Expectations Chimeric antigen receptor (CAR-T) therapy was first approved by the US FDA back in 2017 amid a great deal of fanfare and high expectations among patients about…

InFocus BACK TO HOME     Patient Engagement in the Era of CAR-T   BACK TO HOME Rendering CGT Genuinely Patient Centric In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers…

InFocus BACK TO HOME Patient Engagement in the Era of CAR-T BACK TO HOME Marc Boutin Global Head of Patient Engagement, novartis SHARE Share on twitter Share on linkedin “How are you today?” For patients, this question may be a challenge. Honest answers can stop a conversation straight away. I know…

InFocus HOMEPAGE Patient Engagement in the Era of CAR-T In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers are seeking to become much more than just purveyors of pills and expand…

BACK TO HOME     Cannabis   BACK TO HOME The Cannabis Companies Behaving Like Biotechs While many Canadian medical cannabis outfits cover the entire value chain, from research and development through to manufacturing and distribution, others – such as Canopy Health and Tetra Bio-Pharma – are taking their cues…

BACK TO HOME     Cannabis   BACK TO HOME The Medical Cannabis Investment Landscape David H. Crean, managing director for Objective Capital Partners, highlights the progress that has been made over the past year in investments in medical cannabis and the outlook for 2019. David H. Crean, managing director for Objective…

BACK TO HOME     Cannabis   BACK TO HOME Canada’s Cannabis Pioneers Go Global As Canada’s emergent medical cannabis industry develops at home, several of the country’s leading companies are seizing opportunities abroad to sell their products, collaborate on research, and establish their nation as the industry’s global leader.…

BACK TO HOME     Cannabis   BACK TO HOME Company Profile: GW Pharmaceuticals Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are the producers of Sativex and Epiodiolex, the former…

BACK TO HOME     Cannabis   BACK TO HOME Five Emerging Trends in Medical Cannabis Five of the key emerging trends in the booming global medical cannabis and cannabinoid medicine industries. Five of the key emerging trends in the booming global medical cannabis and cannabinoid medicine industries. SHARE Share…

cannabis BACK TO HOME     Cannabis   BACK TO HOME Patents: A Key Factor in Winning the Cannabis Arms Race A new white paper from Fasken law firm asserts that the early filing of patents for innovative products is crucial for companies hoping to succeed in the booming North American cannabis…